Therapeutic drug monitoring (TOM) has a relatively brief history in clinical laboratories,I beginning in the mid-1970s. Early work described the assistance TOM could provide in tailoring drug dosage to individual patients.P" thereby improving the efficacy of treatment and reducing the incidence of toxicity, and this has been amply confirmed since then. However, as drug analyses have become part of the established repertoire of the clinical laboratory, the ordering of these analyses has become a matter of routine rather than of careful thought. In recent years, a number of authors have suggested that TOM analyses are now being widely misused in clinical practice. 5-1l This review examines extra-laboratory factors which contribute to the overall effectiveness of a TOM service, and seeks to indicate where problems can occur and suggest how they may be resolved.
The original criteria for drug measurements to be clinically worthwhile (as summarised by MuckloW l 2 ; see also Werner et al. 13 ) specified that the drug in question should have:
(a) a rapidly reversible effect (b) a close and predictable relationship between concentration and effect (c) a low therapeutic ratio (d) no active metabolites Initial studies with phenytoin established that these criteria were applicable," and there is no doubt that the widespread availability of plasma phenytoin assays has greatly improved the clinical use of phenytoin. However, drugs that do not conform to the original criteria are now routinely measured by many TOM services 6 - carbamazepine and procainamide have been assigned therapeutic ranges despite the presence of a metabolite which contributes to their effect, and sodium valproate concentrations are frequently measured despite considerable doubt over the existence of a concentrationeffect relationship. IS. 16 Even if a particular drug is worth measuring, a number of additional requirements must be satisfied before individual requests are clinically valuable. These may be summarised as:
(a) a rationalIndication for the request (b) an appropriate specimen (c) an accurate analysis (d) a correct interpretation (e) an appropriate response Requirements (a), (b), (d) and (e) will now be considered in more detail. The requirement for an accurate analysis (c) will not be discussed, since this has been considered elsewhere'? and it is the author's belief that the major challenge facing TOM workers today lies outside and not within the laboratory, in ensuring that TOM data is correctly obtained and appropriately applied.
The extent of the problem
A number of studies, the majority from the USA, have attempted an audit of current practice in TOM, with reference to the criteria listed above. Studies have generally been based on a retrospective review of case records by a panel of specialists (pharmacists, clinical pharmacologists, neurologists etc), and have sought to assess whether an appropriate indication for assay was present, whether the sample was taken at the right time and whether the result was correctly interpreted and acted upon. Some studies then went on to combine these requirements, and only if all three aspects were satisfactory was the request considered to be a valid use of the TOM service. The criteria employed naturally varied between studies, but many of the American studies used the criteria suggested by Levin et al. 18 and adopted in slightly modified form by the American Society of Hospital Pharmacists.P: 20 A selection of such studies" 9. 21-35 is summarised in Table 1 .
It is evident that many (two-thirds or more in some surveys) requests for TOM are inadequately thought out, badly executed or misinterpreted. Requesting clinicians seem unclear when TOM would be helpful, and reluctant to pay proper attention to the results once obtained.7. 35. 36 The consequences of this are an increasing workload for analytical laboratories and considerable wastage of analytical and financial resources. These are serious grounds for concern in themselves, but there is also evidence that inappropriate usage of TOM services harms patients. Beardsley and co-workers'? studied seizure control in a group of epileptic patients following the introduction of drug level monitoring. When the requesting physician made appropriate use of the TOM data, seizure control was improved in 51% of patients and unchanged in 30%, while in cases where the physician was judged to have used the data inappropriately, seizure control was unchanged in 63% of patients and worse in 32%. Beardsley et aI. 30 note that the year before anticonvulsant TOM was available in their hospital and the year following its introduction showed no difference in seizure control, incidence of toxicity or prescribing habits, because physicians were not using the data appropriately. Dobbs and co-workers'! have recently concluded that the measurement of serum digoxin concentrations may be more of a hindrance than a help to optimising dosage, unless considerable time and effort is expended to ensure accurate sampling and proper interpretation.
Clearly, notwithstanding the efforts made by analysts to produce high quality drug determinations, the availability of accurate TOM data does not in itself guarantee improved patient management. It is necessary to ensure that drug measurements are performed only on those patients who will benefit from them, that the specimens are properly collected and that the requesting physician makes effective use of the data obtained. This is not simply a question of limiting the number of requests, for there is evidence that many patients who could benefit from TOM are not having drug levels measured. 3 1 • 37 However, the majority of published surveys have dealt with inappropriate requests rather than omitted requests, and the remainder of this review will consider these further, under the headings outlined above.
INDICATION FOR ANALYSIS
The first essential for making effective use of any laboratory test is to be clear from the outset what question is being asked. This is particularly true of TOM requests, and the widespread failure to define the indication for particular analyses is at the root of most of the problems currently facing TOM. If it is not clear what the question is, the answer is of little value. 311 Some questions to which TOM can provide effective answers are shown in Table 2 . However, much ordering of TOM analyses is done simply because a patient is on the particu- Therapeutic drug monitoring 123 aminoglycoside antibiotics) require peak and trough levels for accurate interpretation.
A mistimed or inappropriately taken specimen can have serious consequences for the patient. Levin et al. 18 cite the case of a patient with a 'toxic' digoxin level whose digoxin was stopped and the patient discharged, only to be readmitted 1 week later in congestive cardiac failure. It was later discovered that the original blood sample was taken 2-3 h after oral dosing, and was therefore invalid.
When computer programs such as ovro are used for pharmacokinetic parameter optimisation and dosage prediction, it becomes extremely important that dosage times and sampling times are accurately known, as large prediction errors can result from poor data. INTERPRETATION Even if a relevant question has been formulated, an appropriate specimen taken and an accurate result obtained, the whole exercise is valueless unless the result is correctly interpreted and any necessary action is taken. Interpretation of plasma drug concentrations requires considerable expertise in some cases, and may be affected by a wide variety of factors." Some examples are shown in Table  3 . 42 -46 Many users of TOM services, however, 'interpret' the results simply by comparing them with the 'therapeutic range' quoted by the laboratory, and then either do nothing or react to bring the levels closer to the quoted range. This is where great harm can occur, since it is frequently forgotten by clinicians as well as laboratory workers that the aim of the TOM process is to ameliorate the patient's symptoms, rather than to get drug levels into a 'therapeutic range'.
The 'therapeutic range' is a synthesis of two concepts--the minimum effective concentra- tion (MEC) of a drug and the maximum safe concentration (MSC). Beween these limits, the majority of patients should experience maximum therapeutic benefit at minimal risk of toxicity and undesirable side effects. However, this simple theory breaks down in a number of important respects, and the 'therapeutic range' must always be considered as a broad guide to assist interpretation rather than a Holy Grail to be attained at all costs. Many workers have suggested that the lower limit of the 'therapeutic range' should be abandoned altogether, since there is much evidence that drugs can be effective in some patients at supposedly 'subtherapeutic' levels. and other patients show no response until levels approaching the upper end of the 'therapeutic range' are attained. The excellent work of Shorvon and Reynolds'? (Table 4) showing how a large proportion of newly diagnosed epileptics can be controlled with a single anticonvulsant drug (phenytoin or carbamazepine) provides good evidence of this while also illustrating the terminological confusion that is all too often generated by the concept of a 'therapeutic range'. Table 4 shows that one quarter of new epileptics (Group 1) were controlled on one anticonvulsant at 'suboptimum' concentration ('optimum' is used as meaning 'within the therapeutic range'). The concentrations achieved in these patients are obviously optimum as far as the patient is concerned, and it may be surmised that the fact that his plasma drug concentration is below a somewhat arbitrary range printed on the report form is of little concern to him. Similarly. 17% of patients in the study could not be controlled at 'optimum' concentrations (Group 5). Clearly. such concentrations are not optimum for the patient concerned, and modest increases in dosage to achieve higher concentrations may achieve control with minimal toxicity. Brodie 4ll reports that some patients are fit-free and untroubled by toxicity with phenytoin levels up to 40 mgIL (160 umol/L).
. As Reynolds" has remarked. the optimum or therapeutic range for any given patient is a very individual matter. which depends in part on the severity of the underlying disease process. This fact does not undermine the value of TOM. but does require a clear understanding of why an individual request has been ordered. and how it can be interpreted in the light of the patient's condition. There is no reason to monitor drug concentrations in a patient who is clinically stable and not showing symptoms of toxicity. except perhaps as a baseline in case problems are subsequently encountered. Difficulties arise when. having made a measurement for no particularly good reason on a stable patient. the clinician discovers that the result is outside the 'therapeutic range' and feels compelIed to do something about it. It must be said that this is sometimes provoked by laboratory workers. some of whom label alI results above the therapeutic range as 'toxic' and telephone them in alarmed tones. In one of the earliest papers on TDM. 3 Koch-Weser wrote: 'Therapeutic decisions should never be based solely on the drug concentration in the serum'. Laboratories could do worse than to print that sentence at the foot of each report. as a reminder to users and themselves. plasma drug levels below the therapeutic range in a patient who is welI and free from symptoms do not require an increase in dosage. although in some cases (eg digoxin and theophylline) they may provide evidence that the drug is not necessary, and stopping it under medical supervision may be tried. 44 The evidence of widespread misuse of TOM services cited above suggests that there is considerable scope for greater involvement by specialists in therapeutic drug monitoring, to ensure that TOM services are used appropriately.
Possible solutions-increased specialist involvement in TDM A number of approaches designed to increase the amount of specialist input into TOM serviceshave been tried, and are summarised in Table 5 . They may be divided according to whether involvement takes place before the specimen is analysed (pre-analysis or 'frontend' intervention) or only after the result has been obtained (post-analysis intervention).
PRE-ANALYSIS INTERVENTION
Clearly, misuse of TOM services is most effectively prevented by pre-analysis intervention. Levin and her colleaguesIII instituted a programme of physician education and required that a pharmacist be involved at the requesting stage for all TOM requests. The results of this are summarised in Table 6 , and it will be seen that after the intervention service was introduced, there was a reduction in the number of analyses performed and a dramatic improvement in the overall effectiveness of the service.
Elenbaas and co-workers'? applied a similar system, and required that all TOM requests be discussed with a clinical pharmacist before the request was sent to the laboratory. Results of the analysis were returned to the clinical pharmacist, who charted the result and made recommendations about appropriate action. The effect was a 40% reduction in the number of analyses performed and the authors reported a similar saving in assay cost, with improved patient care. The savings made on unnecessary assays were more than sufficient to pay for the additional pharmacist involvement. Appreciable cost savings have also been documented by Kimelblatt et al. sl when pharmacist intervention in an aminoglycoside monitoring service was introduced, although in this study the savings were largely due to the substitution of gentamicin for the more expensive tobramycin. This degree of involvement is the ideal situation, but staffing considerations will make it impractical for many hospitals. However, a great deal can still be achieved at less cost in personnel terms. Screening requests after they arrive in the laboratory is effective, and does not require 24-h availability of specialist staff. It is essential to this approach that the request form contains full information on the reason for analysis, the time of the specimen in relation to the last dose, length of time on therapy, other prescribed drugs and the clinical status of the patient. If the specimen or the reason for analysis is inappropriate, specialist laboratory staff can contact the clinician and suggest a course of action. Screening requests in this way requires that request forms be properly completed, and any requests that do not contain essential information should be refused, or at least shelved until the information is provided. Such a proposal may sound obstructive and unnecessary to some, but it is an essential part of the work of the analytical laboratory to ensure that the results produced are being used appropriately. It is worth noting in this context that Clague and co-workers'" found that the refusal of the laboratory to issue a report on digoxin requests that were not accompanied by a properly completed request form 'would have had virtually no impact on the care of the patients involved', since the results of these requests were largely ignored.
POST-ANALYSIS INTERVENTION
Intervention after the analysis has been performed is obviously less effective in reducing the number of inappropriate requests, but nonetheless has a role in improving the use that is made of TOM services. However, it still requires specialist expertise in providing interpretation-simply glancing at the result and writing 'toxic' if it is above the 'therapeutic range' or 'subtherapeutic' if it is below it almost certainly does more harm than good. Richardsorrf has shown that the use of a computer program which takes previous drug levels and pregnancy into account before printing an interpretative comment automatically : on the report can increase the percentage of anticonvulsant results which fall within the 'therapeutic range', although it should be stressed again that this does not necessarily imply improved patient care.
Hom et al. 32 describe a study in which abnormal digoxin results obtained by the routine analytical service were referred to a pharmacist who evaluated the significance of the finding and made recommendations to the clinical staff. They showed that the percentage of appropriate samples rose from 68% to 79% with intervention by the pharmacist, and the number of results within the 'therapeutic range' increased from 50% to 75%. However, of considerably greater interest was the finding that the incidence of digoxin toxicity after the initial sample had been taken fell from 11·1% to 2·6% with pharmacist intervention, and the mean length of bed stay of the patients studied fell from 15·3 days to 11·6 days, indicating a remarkable improvement in patient care at less cost to the hospital. They also noted that only 26 of the 38 recommendations made by the pharmacist were actually followed by the clinician treating the patient, showing scope for still further improvement! In a similar study, Koren et al. 53 have shown that the incidence of drug toxicity can be dramatically reduced by direct notification of potentially toxic results to a clinical pharmacist! pharmacologist, who advises the house staff accordingly.
Conclusion
Therapeutic drug monitoring has a vital role to play in tailoring drug therapy to the individual patient for drugs such as phenytoin, theophylline, lithium and the aminoglycoside antibiotics. However, the availability of accurate TOM data does not in itself improve symptom control or reduce the incidence of toxicity. There is widespread misuse of TOM services at the present time, which is wasting resources and harming patient care. This is particularly evident with digoxin analyses." II. 9. II but attention has recently been drawn to the overuse of measurements of plasma concentrations of anti-epileptic drugs. J() To combat these abuses. greater involvement of specialist personnel. whether pharmacist, clinical pharmacologist or clinical biochemist is required, preferably at ward level. Inappropriate or poorly documented requests should be refused by analytical laboratories.
In an editorial on TOM published in 1985, The Lancet commented 'If plasma drug assays are to be done. they must be accompanied by some form of education system that tells the prescribing doctor the meaning of the result and what steps should now be taken'." It will be clear from the foregoing discussion that this education system can take various forms according to staffing levels and local circumstances, but it is vitally important in providing effective patient management and conserving resources. The potential cost savings are such that the employment of additional adviso7. personnel can be shown to be cost-effective. 1 A'I Whiting 54 has pointed out in his plea for a multi-disciplinary approach, the value of TOM will always reflect the effort put into it. Great progress has been made over the last 10years in improving the analytical quality of TOM analyses. It would be tragic if all this work were to be wasted on producing uninterpretable and clinically irrelevant numbers.
